HIGHLIGHTS
- who: Andrea Galitzia and collaborators from the Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy have published the research work: Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine, in the Journal: Vaccines 2022, 10, x FOR PEER REVIEW of 19/07/2022
- what: The authors conducted a single-center study with the main objective to evaluate the immunogenicity of the BNT1162b2 mRNA vaccines in 42 patients affected by CLL with the assessment of antibody response after the second and the third dose . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.